|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cancer of Stomach | |||||
| Gastroesophageal Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Neoplasm Metastasis | |||||
| Stomach Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Gastrointestinal Diseases | |||||
| Gastrointestinal Neoplasms | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Neoplastic Processes | |||||
| Pathologic Processes | |||||
| Stomach Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Pegamotecan | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Camptothecin | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Enzon Pharmaceuticals, Inc. | |||||